However, this is a guideline, not a strict rule
Patients should be monitored for serious adverse events including pancreatitis (severe abdominal pain radiating to the back, with or without vomiting), gallbladder disease, acute kidney injury (particularly with dehydration from persistent GI symptoms), diabetic retinopathy complications (with Ozempic/Rybelsus), and hypoglycemia (especially when used with insulin or sulfonylureas)
GLP-1 agonistssuch as semaglutide (Ozempic) and tirzepatide (Mounjaro)have revolutionized diabetes and weight management
Here's why many of our patients in Woodbury and St
In general, semaglutide (Wegovy ) and tirzepatide (Zepbound ) are FDA-approved for weight loss in people with: A BMI of 30 or higher , or A BMI of 27 or higher with at least one weight-related condition, like type 2 diabetes or high blood pressure Each medication also has additional FDA-approved uses beyond weight loss: Wegovy is also approved to reduce the risk of major cardiovascular events like heart attack and stroke in adults with cardiovascular disease
Does Cagrilintide slow gastric emptying
